The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer

Journal of Urology

Volumn 169, Issue 4, 2003, Pages 1219-1228

  Smith, Norm D ^a   Rubenstein, Jonathan N ^a   Eggener, Scott E ^a   Kozlowski, James M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Bladder neoplasms; Carcinoma, transitional cell; Genes, p53; Genes, tumor suppressor; Protein p53

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; AUTOANTIBODY; ONYX 015; PROTEIN ANTIBODY; PROTEIN MDM2; PROTEIN P53; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADVANCED CANCER; APOPTOSIS; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CELL FUNCTION; CLINICAL TRIAL; CYSTECTOMY; DNA DAMAGE; DNA REPAIR; GENE CONTROL; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; GENOME; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MEDLINE; MUSCLE METASTASIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0037377269     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000056085.58221.80     Document Type: Review

References (75)

1. Linzer, D. I. and Levine, A. J.: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell, 17: 43, 1979
2. Finlay, C. A., Hinds, P. W. and Levine, A. J.: The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083, 1989
3. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. and Vogelstein, B.: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249: 912, 1990
4. Ko, L. J. and Prives, C.: p53: puzzle and paradigm. Genes Dev, 10: 1054, 1996
5. Levine, A. J.: p53, the cellular gatekeeper for growth and division. Cell, 88: 323, 1997
6. Hollstein, M., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sorlie, T. et al: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res, 22: 3551, 1994
7. DeWolf, W. C.: p53: an important key to understanding urologic cancer. AUA Update Series, vol. XIV, p. 258, 1995
8. Guidos, C. J., Williams, C. J., Grandal, I., Knowles, G., Huang, M. T. and Danska, J. S.: V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev, 10: 2038, 1996
9. Linke, S. P., Clarkin, K. C., DiLeonardo, A., Tsou, A. and Wahl, G. M.: A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev, 10: 934, 1996
10. Gottlieb, T. M. and Oren, M.: p53 in growth control and neoplasia. Biochim Biophys Acta, 1287: 77, 1996
11. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A, and Jacks, T.: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362: 847, 1993
12. Wagner, A. J., Kokontis, J. M. and Hay, N.: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev, 8: 2817, 1994
13. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M.: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352: 345, 1991
14. Johnson, P., Chung, S. and Benchimol, S.: Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol, 13: 1456, 1993
15. Maheswaran, S., Englert, C., Bennett, P., Heinrich, G. and Haber, D. A.: The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev, 9: 2143, 1995
16. Fukasawa, K., Choi, T., Kuriyama, R., Rulong, S. and Vande Woude, G. F.: Abnormal centrosome amplification in the absence of p53. Science, 271: 1744, 1996
17. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L. et al: A p53-dependent mouse spindle checkpoint. Science, 267: 1353, 1995
18. Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H. et al: p53 mutant mice that display early ageing-associated phenotypes. Nature, 415: 45, 2002
19. Bouck, N.: P53 and angiogenesis. Biochim Biophys Acta, 1287: 63, 1996
20. Volpert, O. V., Stellmach, V. and Bouck, N.: The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat, 36: 119, 1995
21. Dameron, K. M., Volpert, O. V., Tainsky, M. A. and Bouck, N.: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265: 1582, 1994
22. Reiher, F., Ozer, O., Pins, M., Jovanovic, B. D., Eggener, S. and Campbell, S. C.: p53 and microvessel density in primary resection specimens of superficial bladder cancer. J Urol, 167: 1469, 2002
23. Lopez-Beltran, A. and Escudero, A. L.: Human papillomavirus and bladder cancer. Biomed Pharmacother, 51: 252, 1997
24. Yu, S. T., Wu, M. M. and Li, L. M.: Prevalence of human papillomaviruses 16 and 18 in transitional cell carcinoma of bladder. Chin Med J, 106: 494, 1993
25. Wu, X., Bayle, J. H., Olson, D. and Levine, A. J.: The p53-mdm-2 autoregulatory feedback loop. Genes Dev, 7: 1126, 1993
26. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W. J. et al: Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst, 86: 1331, 1994
27. Walker, K. K. and Levine, A. J.: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A, 93: 15335, 1996
28. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J. et al: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer, 56: 347, 1994
29. Esrig, D., Spruck, C. H., 3rd, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S. et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer Am J Pathol, 143: 1389, 1993
30. Vet, J. A., Witjes, J. A., Marras, S. A., Hessels, D., van der Poel, H. G., Debruyne, F. M. et al: Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res, 2: 1055, 1996
31. Righi, E., Rossi, G., Ferrari, G., Dotti, A., De Gaetani, C., Ferrari, P. et al: Does p53 immunostaining improve diagnostic accuracy in urine cytology? Diagn Cytopathol, 17: 436, 1997
32. WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol, 161: 792, 1999
33. Casetta, G., Gontero, P., Russo, R., Pacchioni, D. and Tizzani, A.: p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Eur Urol, 32: 229, 1997
34. Holmäng, S., Andius, P., Hedelin, H., Wester, K., Busch, C. and Johansson, S. L.: Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol, 165: 1124, 2001
35. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R. et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst, 85: 53, 1993
36. Hermann, G. G., Horn, T. and Steven, K.: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol, 159: 91, 1998
37. Vatne, V., Maartmann-Moe, H. and Hoestmark, J.: The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol, 29: 491, 1995
38. Bernardini, S., Billerey, C., Martin, M., Adessi, G. L., Wallerand, H. and Bittard, H.: The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol, 165: 42, 2001
39. Caliskan, M., Turkeri, L. N., Mansuroglu, B., Toktas, G., Aksoy, B., Unluer, E. et al: Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol, 79: 373, 1997
40. Ick, K., Schultz, M., Stout, P. and Fan, K.: Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment. Urology, 49: 541, 1997
41. Lacombe, L., Dalbagni, G., Zhang, Z. F., Cordon-Cardo, C., Fair, W. R., Herr, H. W. et al: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette- Guerin therapy: correlation to clinical outcome. J Clin Oncol, 14: 2646, 1996
42. Pages, F., Flam, T. A., Vieillefond, A., Molinie, V., Abeille, X., Lazar, V. et al: p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol, 159: 1079, 1998
43. Moch, H., Sauter, G., Moore, D., Mihatsch, M. J., Gudat, F. and Waldman, F.: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol, 423: 329, 1993
44. Lipponen, P. K.: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer, 53: 365, 1993
45. Qureshi, K. N., Griffiths, T. R., Robinson, M. C., Marsh, C., Roberts, J. T., Hall, R. R. et al: TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res, 5: 3500, 1999
46. Herr, H. W., Bajorin, D. F., Scher, H. I., Cordon-Cardo, C. and Reuter, V. E.: Can p53 help select patients with invasive bladder cancer for bladder preservation? J Urol, 161: 20, 1999
47. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F. et al: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol, 13: 1384, 1995
48. Wu, C. S., Pollack, A., Czerniak, B., Chyle, V., Zagars, G. K., Dinney, C. P. et al: Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology, 47: 305, 1996
49. Jahnson, S., Risberg, B., Karlsson, M. G., Westman, G., Bergstrom, R. and Pedersen, J.: p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol, 28: 135, 1995
50. Rotterud, R., Berner, A., Holm, R., Skovlund, E. and Fossa, S. D.: p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int, 88: 202, 2001
51. Fossa, S. D., Berner, A. A., Jacobsen, A. B., Waehre, H., Kvarstein, B., Urnes, T. et al: Clinical significance of DNA ploidy and S-phase fraction and their relation to p53 protein, c-erbB-2 protein and HCG in operable muscle-invasive bladder cancer. Br J Cancer, 68: 572, 1993
52. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C. et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med, 331: 1259, 1994
53. Kuczyk, M. A., Bokemeyer, C., Serth, J., Hervatin, C., Oelke, M., Hofner, K. et al: p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer, 31A: 2243, 1995
54. Tiguert, R., Bianco, F. J., Jr., Oskanian, P., Li, Y., Grignon, D. J., Wood, D. P., Jr. et al: Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. J Urol, 166: 2155, 2001
55. Fleshner, N., Kapusta, L., Ezer, D., Herschorn, S. and Klotz, L.: p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol, 164: 1177, 2000
56. Van Der Poel, H. G., Hessels, D., Van Leenders, G. J. L. H., Bussemakers, M. J. G., Schalken, J. A., Witjes, J. A. et al: Multifocal transitional cell cancer and p53 mutation analysis. J Urol, 160: 124, 1998
57. Holmäng, S., Hedelin, H., Anderström, C. and Johansson, S. L.: The relationship among multiple recurrences, progression and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol, 153: 1823, 1995
58. Cheng, L., Neumann, R. M., Weaver, A. L., Spotts, B. E. and Bostwick, D. G.: Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol, 17: 3182, 1999
59. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F., Sheinfeld, J. et al: Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol, 152: 388, 1994
60. waf1-Cip1 during treatment of superficial bladder cancer. J Urol, 162: 225, 1999
61. Schmitz-Dräger, B. J., Goebell, P. J., Heydthausen, M. and The International Study Initiative on Bladder Cancer (ISBC): P53 immunohistochemistry as a prognostic marker in bladder cancer: the ISBC combined analysis. J Urol, suppl., 161: 153, abstract 585, 1999
62. Ogura, K., Habuchi, T., Yamada, H., Ogawa, O. and Yoshida, O.: Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int J Urol, 2: 302, 1995
63. Ribeiro, J. C., Barnetson, A. R., Fisher, R. J., Mameghan, H. and Russell, P. J.: Relationship between radiation response and p53 status in human bladder cancer cells. Int J Radiat Biol, 72: 11, 1997
64. Ong, F., Moonen, L. M., Gallee, M. P., ten Bosch, C., Zerp, S. F., Hart, A. A. et al: Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol, 61: 169, 2001
65. Kawasaki, T., Tomita, Y., Bilim, V., Takeda, M., Takahashi, K. and Kumanishi, T.: Abrogation of apoptosis induced by DNA-damaging agents in human bladder- cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer, 68: 501, 1996
66. Cote, R. J. and Chatterjee, S. J.: Molecular determinants of outcome in bladder cancer. Cancer J Sci Am, 5: 2, 1999
67. Waldman, T., Lengauer, C., Kinzler, K. W. and Vogelstein, B.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381: 713, 1996
68. Kielb, S. J., Shah, N. L., Rubin, M. A. and Sanda, M. G.: Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. J Urol, 166: 482, 2001
69. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H. et al: In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res, 60: 1193, 2000
70. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D. and Kirn, D. H.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med, 3: 639, 1997
71. Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R. et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res, 6: 798, 2000
72. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L. et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med, 6: 879, 2000
73. Wada, Y., Gotoh, A., Shirakawa, T., Hamada, K. and Kamidono, S.: Gene therapy for bladder cancer using adenoviral vector. Mol Urol, 5: 47, 2001
74. Irie, A., Uchida, T., Ishida, H., Matsumoto, K., Iwamura, M. and Baba, S.: p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells. Mol Urol, 5: 53, 2001
75. Lang, C., Unteregger, G., Kartarius, S., Gunther, J., Bonkhoff, H., Montenarh, M. et al: p53 autoantibodies in patients with urological tumours. Br J Urol, 82: 721, 1998